Pfizer 1Q Revenues: $12.0 billion (-8%) 1Q Earnings: $3.4 billion (-12%) Comments: Biopharma revenues were up 11% to $10.0 billion. Eliquis sales were up 29% to $1.3 billion in the quarter. Vyndaqel sales were $231 million in the quarter compared to $41 million in 1Q19. Ibrance sales were up 10% to $1.2 billion. Prevenar 13 sales were down 2% to $1.5 billion. Inlyta sales were $169 million in the quarter compared to $73 million in 1Q19. Xeljanz sales were up 7% to $451 million. Xtandi sales w...